Literature DB >> 25295933

Reply: the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia.

S Tiong Ong1, Charles T H Chuah2, Tun Kiat Ko3, Axel M Hillmer4, Wan-Teck Lim5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25295933     DOI： 10.1038/nm.3652

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  9 in total

1.  A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction.

Authors:  Yoshinori Shinohara; Naoto Takahashi; Kaichi Nishiwaki; Masayuki Hino; Makoto Kashimura; Hisashi Wakita; Yoshiaki Hatano; Akira Hirasawa; Yasuaki Nakagawa; Kuniaki Itoh; Hidekazu Masuoka; Nobuyuki Aotsuka; Yasuhiro Matsuura; Sinobu Takahara; Koji Sano; Jun Kuroki; Tomoko Hata; Hirohisa Nakamae; Atsuko Mugitani; Takahiko Nakane; Yasushi Miyazaki; Takenori Niioka; Masatomo Miura; Kenichi Sawada
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

2.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Authors:  King Pan Ng; Axel M Hillmer; Charles T H Chuah; Wen Chun Juan; Tun Kiat Ko; Audrey S M Teo; Pramila N Ariyaratne; Naoto Takahashi; Kenichi Sawada; Yao Fei; Sheila Soh; Wah Heng Lee; John W J Huang; John C Allen; Xing Yi Woo; Niranjan Nagarajan; Vikrant Kumar; Anbupalam Thalamuthu; Wan Ting Poh; Ai Leen Ang; Hae Tha Mya; Gee Fung How; Li Yi Yang; Liang Piu Koh; Balram Chowbay; Chia-Tien Chang; Veera S Nadarajan; Wee Joo Chng; Hein Than; Lay Cheng Lim; Yeow Tee Goh; Shenli Zhang; Dianne Poh; Patrick Tan; Ju-Ee Seet; Mei-Kim Ang; Noan-Minh Chau; Quan-Sing Ng; Daniel S W Tan; Manabu Soda; Kazutoshi Isobe; Markus M Nöthen; Tien Y Wong; Atif Shahab; Xiaoan Ruan; Valère Cacheux-Rataboul; Wing-Kin Sung; Eng Huat Tan; Yasushi Yatabe; Hiroyuki Mano; Ross A Soo; Tan Min Chin; Wan-Teck Lim; Yijun Ruan; S Tiong Ong
Journal:  Nat Med       Date:  2012-03-18       Impact factor: 53.440

3.  The BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia.

Authors:  Xue Chen; Hongxing Liu; Haizhou Xing; Hui Sun; Ping Zhu
Journal:  Nat Med       Date:  2014-10       Impact factor: 53.440

4.  Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.

Authors:  Stephane Picard; Karine Titier; Gabriel Etienne; Emmanuelle Teilhet; Dominique Ducint; Marie-Agnes Bernard; Regis Lassalle; Gerald Marit; Josy Reiffers; Bernard Begaud; Nicholas Moore; Mathieu Molimard; Francois-Xavier Mahon
Journal:  Blood       Date:  2006-12-27       Impact factor: 22.113

5.  Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure.

Authors:  Jorge Cortes; John M Goldman; Timothy Hughes
Journal:  J Natl Compr Canc Netw       Date:  2012-10-01       Impact factor: 11.908

6.  Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer.

Authors:  Jih-Hsiang Lee; Yu-Lin Lin; Wei-Hsun Hsu; Hsuan-Yu Chen; Yeun-Chung Chang; Chong-Jen Yu; Jin-Yuan Shih; Chia-Chi Lin; Kuan-Yu Chen; Chao-Chi Ho; Wei-Yu Laio; Pan-Chyr Yang; James Chih-Hsin Yang
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

7.  Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.

Authors:  J K Lee; J-Y Shin; S Kim; S Lee; C Park; J-Y Kim; Y Koh; B Keam; H S Min; T M Kim; Y-K Jeon; D-W Kim; D H Chung; D S Heo; S-H Lee; J-I Kim
Journal:  Ann Oncol       Date:  2013-04-04       Impact factor: 32.976

8.  The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.

Authors:  Mingchuan Zhao; Yishi Zhang; Weijing Cai; Jiayu Li; Fei Zhou; Ningning Cheng; Ruixin Ren; Chao Zhao; Xuefei Li; Shengxiang Ren; Caicun Zhou; Fred R Hirsch
Journal:  Cancer       Date:  2014-04-15       Impact factor: 6.860

9.  Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation.

Authors:  Kazutoshi Isobe; Yoshinobu Hata; Naobumi Tochigi; Kyohei Kaburaki; Hiroshi Kobayashi; Takashi Makino; Hajime Otsuka; Fumitomo Sato; Fumiaki Ishida; Naoshi Kikuchi; Nao Hirota; Keita Sato; Go Sano; Keishi Sugino; Susumu Sakamoto; Yujiro Takai; Kazutoshi Shibuya; Akira Iyoda; Sakae Homma
Journal:  J Thorac Oncol       Date:  2014-04       Impact factor: 15.609
  9 in total
  3 in total

Review 1.  The genetics of drug efficacy: opportunities and challenges.

Authors:  Matthew R Nelson; Toby Johnson; Liling Warren; Arlene R Hughes; Stephanie L Chissoe; Chun-Fang Xu; Dawn M Waterworth
Journal:  Nat Rev Genet       Date:  2016-03-14       Impact factor: 53.242

2.  The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.

Authors:  Hou-Qun Ying; Jie Chen; Bang-Shun He; Yu-Qin Pan; Feng Wang; Qi-Wen Deng; Hui-Ling Sun; Xian Liu; Shu-Kui Wang
Journal:  Sci Rep       Date:  2015-06-15       Impact factor: 4.379

3.  Impact of the Bim Deletion Polymorphism on Survival Among Patients With Completely Resected Non-Small-Cell Lung Carcinoma.

Authors:  Jun Atsumi; Kimihiro Shimizu; Yoichi Ohtaki; Kyoichi Kaira; Seiichi Kakegawa; Toshiteru Nagashima; Yasuaki Enokida; Seshiru Nakazawa; Kai Obayashi; Yoshiaki Takase; Osamu Kawashima; Mitsuhiro Kamiyoshihara; Masayuki Sugano; Takashi Ibe; Hitoshi Igai; Izumi Takeyoshi
Journal:  J Glob Oncol       Date:  2015-12-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.